← Leaderboards
Chengwen Li
Univ Of North Carolina Chapel Hill
$10,504,911
Attributed
$17,435,298
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,435,298 · 14
By mechanism
R01$13,641,648 · 7
P01$1,684,893 · 2
R41$1,114,892 · 4
R42$993,865 · 1
Top collaborators
- Richard J Samulski20 shared
- Timothy Charles Nichols12 shared
- Charles H Askew1 shared
- Junjiang Sun1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Richard J Samulski$19,583,832
- Jianke Tie$2,076,281
- Nigel S Key$14,906,926
- Aaron L Fogelson$5,408,600
- Jessica Lea Hoffman$578,291
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorClinical TrialsDependovirusAdeno-Associated Viral VectorMediatingMutantCapsidAnimal ModelIn VitroSerotypingLiverNeutralizing AntibodyHemophilia AProteinsDoseHepatocyteBloodVirionIn VivoHemophilia BPreventCanis FamiliarisBase
Grant awards (47)
Novel strategy to block AAV neutralizing antibody activity$993,865
R42 · FY2025 · TR
Novel strategy to block Nabs for AAV gene delivery$601,627
R01 · FY2025 · AI · contact PI
Intramuscular Administration of AAV Vectors Encoding soluble PD-L1 for Rheumatoid Arthritis Treatment$304,502
R41 · FY2025 · AR
Novel strategy to block Nabs for AAV gene delivery$617,680
R01 · FY2024 · AI · contact PI
Development of AAV vectors for CF therapy$388,750
R01 · FY2024 · HL
Novel strategy to block Nabs for AAV gene delivery$579,400
R01 · FY2023 · AI · contact PI
Development of AAV vectors for CF therapy$388,750
R01 · FY2023 · HL
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$625,580
R01 · FY2022 · HL · contact PI
Novel strategy to block Nabs for AAV gene delivery$578,782
R01 · FY2022 · AI · contact PI
Development of AAV vectors for CF therapy$388,750
R01 · FY2022 · HL
Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion$261,080
R41 · FY2022 · DK · contact PI
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$627,135
R01 · FY2021 · HL · contact PI
Development of AAV vectors for CF therapy$388,750
R01 · FY2021 · HL
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$488,270
R01 · FY2020 · HL · contact PI
Enhance AAV Liver Transduction with Capsid Immune Evasion$385,642
R01 · FY2020 · AI · contact PI
Novel strategy to block AAV neutralizing anitbody activity$300,000
R41 · FY2020 · AI · contact PI
Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion$249,310
R41 · FY2020 · HL · contact PI
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors$488,270
R01 · FY2019 · HL · contact PI
Enhance AAV Liver Transduction with Capsid Immune Evasion$380,000
R01 · FY2019 · AI · contact PI
Enhance AAV Liver Transduction with Capsid Immune Evasion$64,380
R01 · FY2019 · AI · contact PI
Enhance AAV Liver Transduction with Capsid Immune Evasion$380,000
R01 · FY2018 · AI · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2018 · HL
Enhance AAV Liver Transduction with Capsid Immune Evasion$380,000
R01 · FY2017 · AI · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2017 · HL
ANIMAL MODELS CORE$270,890
P01 · FY2017 · HL · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2016 · HL
Enhance AAV Liver Transduction with Capsid Immune Evasion$380,000
R01 · FY2016 · AI · contact PI
AAV Gene Therapy for AAT Deficiency$319,241
R01 · FY2016 · DK · contact PI
ANIMAL MODELS CORE$264,245
P01 · FY2016 · HL · contact PI
Directed evolution of AAV vectors for hemophilia to evade neutralization$380,000
R01 · FY2015 · HL
AAV Gene Therapy for AAT Deficiency$319,241
R01 · FY2015 · DK
ANIMAL MODELS CORE$164,348
P01 · FY2015 · HL · contact PI
ANIMAL MODELS CORE$164,347
P01 · FY2015 · HL · contact PI
CTL response to AAV Vector$363,116
R01 · FY2014 · AI
AAV Gene Therapy for AAT Deficiency$319,241
R01 · FY2014 · DK
ANIMAL MODELS CORE$247,132
P01 · FY2014 · HL · contact PI
ANIMAL MODELS CORE$247,131
P01 · FY2014 · HL · contact PI
CTL response to AAV Vector$341,329
R01 · FY2013 · AI
ANIMAL MODELS CORE$326,800
P01 · FY2013 · HL · contact PI
AAV Gene Therapy for AAT Deficiency$308,068
R01 · FY2013 · DK
CTL response to AAV Vector$363,116
R01 · FY2012 · AI
AAV Gene Therapy for AAT Deficiency$319,241
R01 · FY2012 · DK
CTL response to AAV Vector$363,116
R01 · FY2011 · AI
CTL response to AAV Vector$366,784
R01 · FY2010 · AI
AAV Gene Therapy for AAT deficiency$295,993
R01 · FY2010 · DK
CTL response to AAV Vector$15,396
R01 · FY2010 · AI
AAV Gene Therapy for AAT deficiency$296,000
R01 · FY2009 · DK